STRYKAGEN CORPORATION
Biotech · Private
Stryka969, a small molecule drug that enhances α7β1 integrin to compensate for dystrophin loss in Duchenne Muscular Dystrophy
- Grants
- $3.9M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy | $5,143 | |
| Federal grant | Department of Health and Human Services · Phase I · Galectin-1 Protein Therapy for Congenital Muscular Dystrophy | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | $747,570 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | $752,426 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | $958,973 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | $994,272 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1732 | Halia Therapeutics, Inc. | — | $27M |
| 1733 | Iterum Therapeutics plc | — | $127M |
| 1734 | Jnana Therapeutics | — | $110M |
| 1735 | STRYKAGEN CORPORATION | — | — |
| 1736 | MB RESEARCH LABORATORIES, INC. | — | — |
| 1737 | EpimedX, LLC | — | — |
| 1738 | Alpha Cognition Inc. | — | $28M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.